Latest News

NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that its Board of Directors has today authorized the Company’s management to implement a stock repurchase program for up to $5 million of the Company’s common shares at any time. The...

Tiziana Life Sciences today announced that Dr. Thomas Adams passed away on January 9, 2022. He served as a member of Tiziana Life Science’s Board of Directors since February 2021.

• - Clinical data from the first patient, after completing 3 out of 6 months, suggest that the treatment was well tolerated with a favorable clinical response
  
  
• - FDA allows...
  
  

NEW YORK, January 6, 2022 - Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that senior management will present at the Biotech Showcase Conference and be available for...

London, 23 December 2021 - Tiziana Life Sciences(Nasdaq: TLSA) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases has added some additional information on its website for shareholders regarding the migration of its UK shares.

The...

London/New York, 21 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Old Tiziana") a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announced on 20 August 2021 that it had formally commenced...